Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer

Targeting metastatic cancer

(2021) Karuna Ganesh et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

(2021) Robert Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

(2020) T. André et al.   ANNALS OF ONCOLOGY

Angiocrine endothelium: from physiology to cancer

(2020) Jennifer Pasquier et al.   Journal of Translational Medicine

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

(2020) Eudocia Q. Lee et al.   CANCER

Tumor cell-derived Angiopoietin-2 promotes metastasis in melanoma

(2020) Ashik Ahmed Abdul Pari et al.   CANCER RESEARCH

Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody

(2020) Mahak Singhal et al.   EMBO Molecular Medicine

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

(2020) Juan Martin-Liberal et al.   BRITISH JOURNAL OF CANCER

Ripretinib: First Approval

(2020) Sohita Dhillon   DRUGS

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

(2020) T.K. Choueiri et al.   ANNALS OF ONCOLOGY

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

(2020) Tim Eisen et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Sulfated glycans engage the Ang–Tie pathway to regulate vascular development

(2020) Matthew E. Griffin et al.   Nature Chemical Biology

Characterization of ANGPT2 mutations associated with primary lymphedema

(2020) Veli-Matti Leppänen et al.   Science Translational Medicine

Timed Ang2-targeted therapy identifies the Angiopoietin-Tie pathway as key regulator of fatal lymphogenous metastasis

(2020) Nicolas Gengenbacher et al.   Cancer Discovery

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vessel co-option in cancer

(2019) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

(2019) Bryan D. Smith et al.   CANCER CELL

The Intersection between Tumor Angiogenesis and Immune Suppression

(2019) Osama E. Rahma et al.   CLINICAL CANCER RESEARCH

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

(2019) Leonard Joseph Appleman et al.   JOURNAL OF CLINICAL ONCOLOGY

Interactions in the (Pre)metastatic Niche Support Metastasis Formation

(2019) Ginevra Doglioni et al.   Frontiers in Oncology

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis

(2019) Meng Xu et al.   CELL

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

(2019) Johanna C. Bendell et al.   ONCOLOGIST

Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma

(2019) May Elbanna et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

(2019) Mariangela Di Tacchio et al.   Cancer Immunology Research

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

(2019) Abhishek S. Kashyap et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Angiopoietin1 Deficiency in Hepatocytes Affects the Growth of Colorectal Cancer Liver Metastases (CRCLM)

(2019) Nisreen S. Ibrahim et al.   Cancers

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

(2018) David M. Hyman et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Blockade across the Cancer Care Continuum

(2018) Beth A. Helmink et al.   IMMUNITY

Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

(2018) Silvia La Porta et al.   JOURNAL OF CLINICAL INVESTIGATION

The new era of adjuvant therapies for melanoma

(2018) Alexander M. M. Eggermont et al.   Nature Reviews Clinical Oncology

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy

(2018) Jordan A. Krall et al.   Science Translational Medicine

Anti-Angiogenics: Current Situation and Future Perspectives

(2018) Katja Zirlik et al.   Oncology Research and Treatment

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

(2018) Kathy D. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab in Resected Stage III Melanoma

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

(2018) M Gross-Goupil et al.   ANNALS OF ONCOLOGY

Fruquintinib: First Global Approval

(2018) Matt Shirley   DRUGS

A framework for the development of effective anti-metastatic agents

(2018) Robin L. Anderson et al.   Nature Reviews Clinical Oncology

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

(2017) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

(2017) Heather A Wakelee et al.   LANCET ONCOLOGY

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization

(2017) Veli-Matti Leppänen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dimerization of Tie2 mediated by its membrane-proximal FNIII domains

(2017) Jason O. Moore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Pericyte-expressed Tie2 controls angiogenesis and vessel maturation

(2017) Martin Teichert et al.   Nature Communications

LBA12FINAL RESULTS FROM QUASAR2, A MULTICENTRE, INTERNATIONAL RANDOMISED PHASE III TRIAL OF CAPECITABINE (CAP) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT SETTING OF STAGE II/III COLORECTAL CANCER (CRC)

(2017) R.S. Midgley et al.   ANNALS OF ONCOLOGY

Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers

(2016) Florence T.H. Wu et al.   CANCER RESEARCH

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors

(2016) A. Dowlati et al.   CLINICAL CANCER RESEARCH

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

(2016) Khalid Al Wadi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

(2016) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

(2016) Minah Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Tie1 controls angiopoietin function in vascular remodeling and inflammation

(2016) Emilia A. Korhonen et al.   JOURNAL OF CLINICAL INVESTIGATION

Adjuvant therapy for renal-cell carcinoma: settled for now

(2016) Stefan Duensing et al.   LANCET

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

(2016) Naomi B Haas et al.   LANCET

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Bevacizumab in colorectal cancer: it should have worked

(2016) Leonard B Saltz   LANCET ONCOLOGY

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

(2016) Rachel S Kerr et al.   LANCET ONCOLOGY

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

(2016) Werner Scheuer et al.   mAbs

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

(2016) Alain Ravaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer

(2016) Florence T. H. Wu et al.   Scientific Reports

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

(2016) Xinqi Wu et al.   Cancer Immunology Research

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

(2015) Véronique Diéras et al.   BREAST

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2015) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2

(2015) F. T. Wu et al.   EMBO Molecular Medicine

Amgen's angiopoietin blocker fails in ovarian cancer

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

Endothelial destabilization by angiopoietin-2 via integrin β1 activation

(2015) Laura Hakanpaa et al.   Nature Communications

A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner

(2015) Nuri Oh et al.   Scientific Reports

The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells

(2015) Soniya Savant et al.   Cell Reports

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

(2014) Kshitij Srivastava et al.   CANCER CELL

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

(2014) DJ Slamon et al.   CANCER RESEARCH

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

(2014) G. Garcia-Manero et al.   CLINICAL CANCER RESEARCH

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

(2014) J. M. Ebos et al.   EMBO Molecular Medicine

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

(2014) Roberto Pili et al.   INVESTIGATIONAL NEW DRUGS

Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy

(2014) Gabriela D’Amico et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature

(2014) Jikui Shen et al.   JOURNAL OF CLINICAL INVESTIGATION

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

(2014) Pippa G Corrie et al.   LANCET ONCOLOGY

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

(2014) Bradley J Monk et al.   LANCET ONCOLOGY

The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma

(2014) Xiaoen Wang et al.   Translational Oncology

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

(2013) M Peeters et al.   BRITISH JOURNAL OF CANCER

Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy

(2013) D. Gerald et al.   CANCER RESEARCH

TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2-Expressing Monocytes in Human Breast Tumors

(2013) M. Ibberson et al.   CLINICAL CANCER RESEARCH

Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression

(2013) Shom Goel et al.   JNCI-Journal of the National Cancer Institute

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

(2013) Markus Thomas et al.   PLoS One

The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases

(2013) Takashi Minami et al.   Cell Reports

A Role for Angiopoietin-2 in Organ-Specific Metastasis

(2013) Nicolò Rigamonti et al.   Cell Reports

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

(2012) M. M. Eatock et al.   ANNALS OF ONCOLOGY

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

(2012) Brian Rini et al.   CANCER

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

(2012) C. Daly et al.   CANCER RESEARCH

G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency

(2012) Jae Hong Im et al.   INTERNATIONAL JOURNAL OF CANCER

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

(2012) Moritz Felcht et al.   JOURNAL OF CLINICAL INVESTIGATION

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

(2012) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis

(2012) Tanja Holopainen et al.   JNCI-Journal of the National Cancer Institute

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

(2012) Aimery de Gramont et al.   LANCET ONCOLOGY

Orchestral actions of angiopoietin-1 in vascular regeneration

(2012) Gou Young Koh   TRENDS IN MOLECULAR MEDICINE

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis: Figure 1.

(2011) Michele De Palma et al.   CLINICAL CANCER RESEARCH

Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

(2011) Marie Jeansson et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Rethinking the metastatic cascade as a therapeutic target

(2011) Lida A. Mina et al.   Nature Reviews Clinical Oncology

Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage

(2010) Young Jun Koh et al.   CANCER CELL

AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective

(2010) J. E. Talmadge et al.   CANCER RESEARCH

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma

(2010) Jo Eyles et al.   JOURNAL OF CLINICAL INVESTIGATION

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

Tie1-Tie2 Interactions Mediate Functional Differences between Angiopoietin Ligands

(2010) Tom C.M. Seegar et al.   MOLECULAR CELL

Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels

(2009) Beverly L. Falcón et al.   AMERICAN JOURNAL OF PATHOLOGY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment

(2009) T. Holopainen et al.   CANCER RESEARCH

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

(2009) Patrick Nasarre et al.   CANCER RESEARCH

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

(2009) J. M. L. Ebos et al.   CLINICAL CANCER RESEARCH

COMP-Ang1 Potentiates the Antitumor Activity of 5-Fluorouracil by Improving Tissue Perfusion in Murine Lewis Lung Carcinoma

(2009) J.-A. Hwang et al.   MOLECULAR CANCER RESEARCH

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia

(2008) Julie Gavard et al.   DEVELOPMENTAL CELL

COMP-Ang1, Angiopoietin-1 Variant Protects Radiation-Induced Bone Marrow Damage in C57BL/6 Mice

(2008) Hae June LEE et al.   JOURNAL OF RADIATION RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE